富国中证医药50ETF联接C(012802)利润分配表
| |
2024-12-31 |
2024-06-30 |
2023-12-31 |
2023-06-30 |
| 收入 |
-21,692,451.23 |
-32,463,738.26 |
-23,789,787.19 |
-16,133,071.84 |
| 利息合计 |
17,784.92 |
7,737.10 |
38,404.25 |
20,262.21 |
| 其中：存款利息收入 |
17,784.92 |
7,737.10 |
38,404.25 |
20,262.21 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-40,286,222.17 |
-16,387,224.24 |
16,298,384.78 |
-1,010,933.39 |
| 其中：股票投资收益 |
46,042.23 |
-71,944.62 |
-38,139.03 |
-44,818.78 |
| 基金投资收益 |
-40,426,770.65 |
-16,386,124.42 |
-4,196,580.43 |
-968,673.75 |
| 债券投资收益 |
85,484.36 |
62,675.47 |
26,452.34 |
2,559.14 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
9,021.89 |
8,169.33 |
20,506,651.90 |
- |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
18,472,933.31 |
-16,128,998.09 |
-40,225,805.86 |
-15,197,108.56 |
| 其他收入 |
103,052.71 |
44,746.97 |
99,229.64 |
54,707.90 |
| 费用 |
279,612.50 |
142,361.19 |
312,322.67 |
150,439.12 |
| 管理人报酬 |
41,530.40 |
21,549.73 |
53,338.23 |
25,832.23 |
| 基金托管费 |
8,306.06 |
4,309.94 |
10,667.62 |
5,166.46 |
| 销售服务费 |
72,245.35 |
38,123.27 |
87,740.92 |
40,150.66 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
2,472.34 |
- |
| 其中：卖出回购金融资产支出 |
- |
- |
2,472.34 |
- |
| 其他费用 |
157,530.69 |
78,378.25 |
158,103.56 |
79,289.77 |
| 利润总额 |
-21,972,063.73 |
-32,606,099.45 |
-24,102,109.86 |
-16,283,510.96 |
微信公众号
证券之星APP
基本资料
